DOP2019000293A - Anticuerpos agonistas contra btla y sus usos - Google Patents

Anticuerpos agonistas contra btla y sus usos

Info

Publication number
DOP2019000293A
DOP2019000293A DO2019000293A DO2019000293A DOP2019000293A DO P2019000293 A DOP2019000293 A DO P2019000293A DO 2019000293 A DO2019000293 A DO 2019000293A DO 2019000293 A DO2019000293 A DO 2019000293A DO P2019000293 A DOP2019000293 A DO P2019000293A
Authority
DO
Dominican Republic
Prior art keywords
antibodies against
agonist antibodies
btla
against btla
antibodies
Prior art date
Application number
DO2019000293A
Other languages
English (en)
Inventor
Krummen Atwell Shane
H Obungu Victor
Charles Vendel Andrew
Original Assignee
Elly Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elly Lilly And Company filed Critical Elly Lilly And Company
Publication of DOP2019000293A publication Critical patent/DOP2019000293A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Se proporcionan anticuerpos que se fijan a BTLA, y métodos para usarlos, en donde dichos anticuerpos son útiles como agentes para tratar afecciones asociadas a la enfermedad autoinmunitaria, que incluyen el tratamiento de lupus.
DO2019000293A 2017-05-19 2019-11-15 Anticuerpos agonistas contra btla y sus usos DOP2019000293A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762508510P 2017-05-19 2017-05-19
PCT/US2018/032218 WO2018213113A1 (en) 2017-05-19 2018-05-11 Btla agonist antibodies and uses thereof

Publications (1)

Publication Number Publication Date
DOP2019000293A true DOP2019000293A (es) 2019-12-15

Family

ID=62245543

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2019000293A DOP2019000293A (es) 2017-05-19 2019-11-15 Anticuerpos agonistas contra btla y sus usos

Country Status (25)

Country Link
US (2) US10604573B2 (es)
EP (1) EP3625257A1 (es)
JP (2) JP6790304B2 (es)
KR (3) KR102294051B1 (es)
CN (3) CN117402244A (es)
AR (1) AR111752A1 (es)
AU (2) AU2018269585B2 (es)
BR (1) BR112019021547A2 (es)
CA (2) CA3064518A1 (es)
CL (1) CL2019003215A1 (es)
CO (1) CO2019012756A2 (es)
CR (1) CR20190521A (es)
DO (1) DOP2019000293A (es)
EA (1) EA201992460A1 (es)
EC (1) ECSP19082184A (es)
JO (1) JOP20190261A1 (es)
MA (1) MA49133A (es)
MX (1) MX2019013604A (es)
MY (1) MY197425A (es)
NZ (1) NZ758360A (es)
PE (1) PE20191843A1 (es)
PH (1) PH12019502575A1 (es)
TW (4) TWI804044B (es)
WO (1) WO2018213113A1 (es)
ZA (1) ZA201906954B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201820554D0 (en) 2018-12-17 2019-01-30 Univ Oxford Innovation Ltd BTLA antibodies
CA3154522A1 (en) 2019-10-15 2021-04-22 Christopher Carl Frye Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
GB202008860D0 (en) 2020-06-11 2020-07-29 Univ Oxford Innovation Ltd BTLA antibodies
AU2021365611A1 (en) * 2020-10-23 2023-06-08 Anaptysbio, Inc. B and t lymphocyte attenuator (btla) modulators and method of using same
WO2023143565A1 (en) * 2022-01-29 2023-08-03 Hifibio (Hk) Limited Anti-btla antibodies and uses thereof in treating cancer
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546541B2 (en) 2002-06-20 2013-10-01 Washington University Compositions and methods for modulating lymphocyte activity
CA2503125C (en) * 2002-10-25 2013-04-30 Hilary Clark Novel composition and methods for the treatment of immune related diseases
JP2010509920A (ja) * 2006-11-15 2010-04-02 メダレックス インコーポレーティッド Ｂｔｌａに対するヒトモノクローナル抗体および使用方法
CA2769473A1 (en) * 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
US9533039B2 (en) * 2010-09-27 2017-01-03 Regeneron Pharmaceuticals, Inc. Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies
WO2014018931A1 (en) * 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
US10005839B2 (en) * 2013-05-17 2018-06-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antagonist of the BTLA/HVEM interaction for use in therapy
EP3288587A4 (en) * 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
EP3383908A1 (en) 2015-12-02 2018-10-10 Stsciences, Inc. Antibodies specific to glycosylated btla (b- and t- lymphocyte attenuator)

Also Published As

Publication number Publication date
EA201992460A1 (ru) 2020-03-18
MX2019013604A (es) 2019-12-18
KR20210106033A (ko) 2021-08-27
KR20220158847A (ko) 2022-12-01
MY197425A (en) 2023-06-16
US11396545B2 (en) 2022-07-26
JP7072622B2 (ja) 2022-05-20
TW201946932A (zh) 2019-12-16
KR102294051B1 (ko) 2021-08-27
AR111752A1 (es) 2019-08-14
ZA201906954B (en) 2021-06-30
CN110621699B (zh) 2023-10-31
BR112019021547A2 (pt) 2020-05-12
TWI747043B (zh) 2021-11-21
TW201904991A (zh) 2019-02-01
JP2020518288A (ja) 2020-06-25
AU2021277743A1 (en) 2021-12-23
CN117402245A (zh) 2024-01-16
TWI677504B (zh) 2019-11-21
CR20190521A (es) 2020-01-06
CA3184628A1 (en) 2018-11-22
US20180334502A1 (en) 2018-11-22
US20200239578A1 (en) 2020-07-30
WO2018213113A1 (en) 2018-11-22
ECSP19082184A (es) 2019-11-30
NZ758360A (en) 2022-10-28
JOP20190261A1 (ar) 2019-11-05
TWI804044B (zh) 2023-06-01
PH12019502575A1 (en) 2020-07-13
JP6790304B2 (ja) 2020-11-25
CA3064518A1 (en) 2018-11-22
JP2021019642A (ja) 2021-02-18
AU2018269585B2 (en) 2021-09-02
TW202334237A (zh) 2023-09-01
CN110621699A (zh) 2019-12-27
EP3625257A1 (en) 2020-03-25
MA49133A (fr) 2020-03-25
KR20190140969A (ko) 2019-12-20
US10604573B2 (en) 2020-03-31
TW202233681A (zh) 2022-09-01
PE20191843A1 (es) 2019-12-31
CN117402244A (zh) 2024-01-16
CO2019012756A2 (es) 2020-01-17
AU2018269585A1 (en) 2019-10-31
CL2019003215A1 (es) 2020-04-13

Similar Documents

Publication Publication Date Title
ECSP19082184A (es) Anticuerpos agonistas contra btla y sus usos
CO2017002719A2 (es) Anticuerpos anti-glucagón
CL2017003404A1 (es) Compuestos antibacterianos
ECSP17070399A (es) Anticuerpos contra icos
UY35417A (es) Anticuerpos dirigidos contra il-33 y sus usos.
CO2018003500A2 (es) Anticuerpos anti-pd-1 y composiciones
CR20190179A (es) Anticuerpos anti-il-33 y usos de estos
AR102712A1 (es) Agonistas parciales del receptor de insulina
CO2017006740A2 (es) Anticuerpos anti–cd79b
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
CL2019002792A1 (es) Composición para producir tagatosa y procedimiento de producción de tagatosa usando el mismo.
PE20171556A1 (es) Agentes de union a cd123 y usos de estos
UY36179A (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
BR112017006520A2 (pt) métodos de tratamento do lúpus eritematoso sistêmico usando um anticorpo de domínio direcionado contra cd28
NI201800134A (es) Anticuerpos antifactor de la coagulación xi
UY35327A (es) ?4,5-dihidro-1,2,4-oxadiazoles disustituidos en 3,5 y composiciones y métodos para controlar plagas de nematodos?.
EA201891376A1 (ru) Бензотиофеновые селективные блокаторы эстрогеновых рецепторов
AR106133A1 (es) Métodos para el tratamiento de la epilepsia
CL2020000655A1 (es) Tratamiento mejorado de dermatitis atópica con tradipitant.
DOP2019000082A (es) Anticuerpos anti-il-33 y usos de los mismos
ECSP17039183A (es) Agonistas parciales del receptor de insulina
AR103227A1 (es) Anticuerpos anti-csf1r para el tratamiento de svp
AR098780A1 (es) Proceso de obtención de micropartículas de quitosano
AR105316A1 (es) Anticuerpos contra el receptor de transferrina (anti-cd71), anticuerpos anti-cd71 activables y sus métodos de uso